We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info
The Anglo-Swedish drugs giant has agreed to a shipment schedule to ensure around 200 million doses of its Oxford-produced jab to be sent to EU nations by the first quarter of next year. The two parties have also agreed to cap rebates that will apply in the event of any further delays to shipments. Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said: “I’m very pleased that we have been able to reach a common understanding which allows us to move forward and work in collaboration with the European Commission to help overcome the pandemic.
“We are fully committed to manufacture Vaxzevria for Europe following the release for supply of more than 140 million doses to date at no profit. We are also looking forward to working with the European Commission in a joint effort to further support COVAX.”
Source: Read Full Article